ARTICLE | Product Development
Where Gilead is looking next in oncology
The company aims to sift through combinations quickly via platform trials, and is outlining its next priority target and technology spaces in cancer
April 16, 2022 12:25 AM UTC
Updated on Apr 19, 2022 at 2:02 AM UTC
Having bulked up its roster of oncology acquisitions, partnerships and personnel, Gilead is shooting for oncology to bring in a third of its total revenue in 2030. The company sees combinations as a major engine for growth, and is turning to platform trials to make speedier decisions about which ones to prioritize.
The commitment to cancer is reflected in headcounts, said Bill Grossman, SVP of oncology clinical development and therapeutic area head. “We’ve hired about 1,100 people since a couple of years ago,” he told BioCentury. The company tripled its U.S. sales force, and more than doubled its medical oncology team...